- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Paladin Labs Announces Approval of Envarsus PA™ in Canada
Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is marketed in Canada by Paladin Labs. As quoted in the press release: “We are pleased to announce Health Canada’s approval of Envarsus PA™ in Canada,” said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. …
Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is marketed in Canada by Paladin Labs.
As quoted in the press release:
“We are pleased to announce Health Canada’s approval of Envarsus PA™ in Canada,” said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. “We believe the launch of Envarsus PA™ will provide kidney or liver transplant patients with an important alternative in immunosuppression, enhancing therapeutic options for those patients and for healthcare providers. We are committed to supporting continued innovation in transplantation to help Canadian patients with unmet needs.”
About Transplantation
The kidney and liver are the two most transplanted organs in Canada, representing over 76% of all organ transplants performed each year1. In patients with end-stage organ failure, organ transplantation is the only curative option and has been established as a life-saving intervention that can have a profound effect on patient outcomes, including health-related quality of life (HRQoL) and survival.2-4 The most serious complication of transplantation is organ rejection and controlling the anti-transplant immune response is essential for a successful outcome.About ENVARSUS PA™
ENVARSUS PA™ (tacrolimus prolonged-release tablets) is indicated for the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Envarsus is currently marketed in Europe and in the US.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.